Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-α signaling

Oncogene

Volumn 33, Issue 13, 2014, Pages 1700-1712

  Kyula, J N ^a   Khan, A A ^a   Mansfield, D ^a   Karapanagiotou, E M ^a   Mclaughlin, M ^a   Roulstone, V ^a   Zaidi, S ^a   Pencavel, T ^a   Touchefeu, Y ^a   Seth, R ^a   Chen, N G ^b   Yu, Y A ^b   Zhang, Q ^b   Melcher, A A ^c   Vile, R G ^c,d   Pandha, H S ^e   Ajaz, M ^e   Szalay, A A ^b   Harrington, K J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GENELUX CORPORATION   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Apoptosis; GLV 1h68; JNK; Oncolytic vaccinia; RT; TNF

Indexed keywords

B RAF KINASE; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; ONCOLYTIC VIRUS; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL DEATH; CELL MUTANT; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DNA MODIFICATION; ENZYME PHOSPHORYLATION; FEMALE; GENOTYPE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR GROWTH; VACCINIA VIRUS; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

GIARDIA LAMBLIA VIRUS; VACCINIA VIRUS;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROTO-ONCOGENE PROTEINS B-RAF; RANDOM ALLOCATION; TUMOR NECROSIS FACTOR-ALPHA; VACCINIA VIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897979547     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.112     Document Type: Article

References (42)

1. Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 2010; 16: 3067-3077
2. Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, et al. REO-10: A phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 2010; 16: 5564-5572
3. Andrade AA, Silva PN, Pereira AC, De Sousa LP, Ferreira PC, Gazzinelli RT, et al. The vaccinia virus-stimulated mitogen-Activated protein kinase (MAPK) pathway is required for virus multiplication. Biochem J. 2004; 381(Pt 2): 437-446
4. De Magalhaes JC, Andrade AA, Silva PN, Sousa LP, Ropert C, Ferreira PC, et al. A mitogenic signal triggered at an early stage of vaccinia virus infection: Implication of MEK/ERK and protein kinase A in virus multiplication. J Biol Chem 2001; 276: 38353-38360
5. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene 2003; 22: 5885-5896
6. Ascierto ML, Worschech A, Yu Z, Adams S, Reinboth J, Chen NG, et al. Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer 2011; 11: 451
7. Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, et al. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 2009; 8: 141-151
8. Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, et al. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: Preclinical development of a therapeutic agent. Cancer Gene Ther 2009; 16: 320-328
9. Yu Z, Li S, Brader P, Chen N, Yu YA, Zhang Q, et al. Oncolytic vaccinia therapy of squamous cell carcinoma. Mol Cancer. 2009; 8: 45
10. Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, et al. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab 2008; 93: 4403-4407
11. Kelly KJ, Woo Y, Brader P, Yu Z, Riedl C, Lin SF, et al. Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. Hum Gene Ther 2008; 19: 774-782
12. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007; 67: 10038-10046
13. Khan N, Khan MK, Almasan A, Singh AD, Macklis R. The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys 2011; 80: 645-654
14. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516
15. Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K, et al. Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral oncology 2012; 49: 108-118
16. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in nonsmall-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5: 2676-2684
17. Greco WR, Bravo G, Parsons JC. The search for synergy: A critical review from a response surface perspective. Pharmacol Reviews 1995; 47: 331-385
18. Bliss CI. The calculation of microbial assays. Bacteriol Reviews 1956; 20: 243-258
19. Wullaert A, Heyninck K, Beyaert R. Mechanisms of crosstalk between TNF-induced NF-kappaB and JNK activation in hepatocytes. Biochem Pharmacol 2006; 72: 1090-1101
20. Gray-Schopfer VC, Karasarides M, Hayward R, Marais R. Tumor necrosis factoralpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res 2007; 67: 122-129
21. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445: 851-857
22. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005; 115: 813-824
23. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009; 15: 6158-6166
24. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol. 2007; 34: 532-545
25. King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 2006; 66: 11100-11105
26. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105: 3041-3046
27. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-221
28. Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009; 15: 7711-7718
29. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-3140
30. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999; 10: 3013-3029
31. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004; 10: 8603-8612
32. Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, et al. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 2011; 11: 221
33. Gutermann A, Mayer E, von Dehn-Rothfelser K, Breidenstein C, Weber M, Muench M, et al. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther 2006; 17: 1241-1253
34. Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008; 14: 912-923
35. Pawlik TM, Nakamura H, Mullen JT, Kasuya H, Yoon SS, Chandrasekhar S, et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002; 95: 1171-1181
36. Tyminski E, Leroy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK, et al. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-Activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 2005; 65: 6850-6857
37. Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, et al. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 2005; 12: 1198-1205
38. Soares JA, Leite FG, Andrade LG, Torres AA, De Sousa LP, Barcelos LS, et al. Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication. J Virol 2009; 83: 6883-6899
39. Wang G, Barrett JW, Stanford M, Werden SJ, Johnston JB, Gao X, et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA 2006; 103: 4640-4645
40. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-Alpha are resistant to skin carcinogenesis. Nature Medicine 1999; 5: 828-831
41. Beyaert R, Van Loo G, Heyninck K, Vandenabeele P. Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas. Int Rev Cytol 2002; 214: 225-272
42. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004; 18: 2195-2224.